Opinion|Videos|August 22, 2024

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

Author(s)Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc, Ricardo D. Parrondo, MD

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

Episodes in this series

5 KOLs are featured in this panel.

EP. 1 Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

5 KOLs are featured in this panel.

EP. 2 Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

5 KOLs are featured in this panel.

EP. 3 Frontline BTKi Selection

5 KOLs are featured in this panel.

EP. 4 Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

5 KOLs are featured in this panel.

EP. 5 Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

5 KOLs are featured in this panel.

EP. 6 Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

5 KOLs are featured in this panel.

EP. 7 EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

5 KOLs are featured in this panel.

EP. 8 Navigating Treatment Approaches for R/R CLL

5 KOLs are featured in this panel.

EP. 9 How Experts View MAIC Data That was Presented at EHA 2024

5 KOLs are featured in this panel.

EP. 10 BTKi Intolerance in Real-world Practice & Management Strategy

5 KOLs are featured in this panel.

EP. 11 Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

5 KOLs are featured in this panel.

EP. 12 Approach to Hypertension Management With BTKi Treatment

5 KOLs are featured in this panel.

EP. 13 Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

5 KOLs are featured in this panel.

EP. 14 Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

A panel of 5 experts on CLL

EP. 15 Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

A panel of 5 experts on CLL

EP. 16 TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

A panel of 5 experts on CLL

EP. 17 EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

A panel of 5 experts on CLL

EP. 18 Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

A panel of 5 experts on CLL

EP. 19 Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

A panel of 5 experts on CLL

EP. 20 Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

A panel of 5 experts on CLL

EP. 21 Clinical Pearls and Impacts to Practice from EHA 2024

Video content above is prompted by the following:

BGB-16673

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, gastric cancer, gastrointestinal stromal tumor, renal cell carcinoma, and chronic lymphocytic leukemia.

August 30th, 2026

Five Under 5: Top Oncology Videos for the Week of 8/23

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC